Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database,...

Full description

Bibliographic Details
Main Authors: Michael Beck, Derralynn Hughes, Christoph Kampmann, Sylvain Larroque, Atul Mehta, Guillem Pintos-Morell, Uma Ramaswami, Michael West, Anna Wijatyk, Roberto Giugliani
Format: Article
Language:English
Published: Elsevier 2015-06-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Fabry disease
Enzyme replacement therapy
Agalsidase alfa
Long-term effectiveness
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426915000099

Internet

http://www.sciencedirect.com/science/article/pii/S2214426915000099

Similar Items